Clinical study of Sl,oxaliplatin,irinotecan and leucovorin combination chemotherapy in advanced gastric cancer

CHEN Jing1; PAN Xing-guo2; NIU Huan-yi3; LIN Yuan1; HUANG Zhi-jie4; ZHANG Ru1

您当前的位置：

首页 >

文章列表页 >

Clinical study of Sl,oxaliplatin,irinotecan and leucovorin combination chemotherapy in advanced gastric cancer

更新时间：2024-01-17

- Clinical study of Sl,oxaliplatin,irinotecan and leucovorin combination chemotherapy in advanced gastric cancer
- Journal of Chongqing Medical University Vol. 36, Issue 11, Pages: 1397-1399(2011)
- 作者机构：
  
  1. 成都军区总医院干部病房
  2. 成都军区总医院放疗科
  3. 成都军区总医院肿瘤科
  4. 成都军区总医院核医学科
- 作者简介：
- 基金信息：
- DOI：
  CLC： R735.2
- Published：2011，
扫描看全文
[1]陈静,潘兴国,牛焕义,林源,黄之杰,张汝.替吉奥胶囊联合奥沙利铂、伊立替康/亚叶酸钙治疗晚期胃癌疗效分析[J].重庆医科大学学报,2011,36(11):1397-1399.

CHEN Jing1, PAN Xing-guo2, NIU Huan-yi3, et al. Clinical study of Sl,oxaliplatin,irinotecan and leucovorin combination chemotherapy in advanced gastric cancer. [J]. Journal of Chongqing Medical University 36(11):1397-1399(2011)
[1]陈静,潘兴国,牛焕义,林源,黄之杰,张汝.替吉奥胶囊联合奥沙利铂、伊立替康/亚叶酸钙治疗晚期胃癌疗效分析[J].重庆医科大学学报,2011,36(11):1397-1399. DOI：

CHEN Jing1, PAN Xing-guo2, NIU Huan-yi3, et al. Clinical study of Sl,oxaliplatin,irinotecan and leucovorin combination chemotherapy in advanced gastric cancer. [J]. Journal of Chongqing Medical University 36(11):1397-1399(2011) DOI：

摘要

目的:观察替吉奥（S1）胶囊联合奥沙利铂与伊立替康/亚叶酸钙治疗晚期胃癌的临床疗效及毒副反应。方法:48例晚期胃癌患者

采用以下化疗方案:替吉奥胶囊80 mg/m2

餐后口服

每天两次

连续服用2周

停药1周;奥沙利铂130 mg/m2

静脉滴注3 h

d1;伊立替康80 mg/m2

d1、d15

5周重复;亚叶酸钙200 mg/m2

静脉滴注d1、d15

28 d为1个周期

至少进行2个周期。按RECIST 1.1标准评价联合治疗的效果和不良反应。结果:48例患者均可以评价。完全缓解（CR）（complete remission）5例（10.4%）

部分缓解（Partial remission

PR）23例（47.9%）

病情稳定（Stable disease

SD）12例（25.0%）

病情进展（Progressiondisease

PD）8例（16.7%）

药物的有效治疗率（Response rate

RR）（58.3%）

统计疾病控制率（Disease control rate

DCR）（83.3%）。中位疾病进展时间（Median time to progression

TTP）为8.9个月

中位生存期（Median survival time

MST）为12.3个月。不良反应主要是外周神经毒性、白细胞减少、中性粒细胞下降、胃肠道反应。结论:替吉奥胶囊联合奥沙利铂、伊立替康/亚叶酸钙治疗晚期胃癌疗效显著

毒副反应能耐受

明显提高患者生活质量

值得临床推广应用。

Abstract

Objective:To investigate the efficacy and safety of S1

oxaliplatin

irinotecan and leucovorin combination chemotherapy in advanced gastric carcinoma.Methods:48 patients with advanced gastric cancer were enrolled.Patients receiving S1

at 80 mg/m2

was orally administered twice daily for 2 weeks

followed by a drug-free interval of 1 week(one cycle).Concurrently

Irinotecan(150 mg/m2) and leucovorin(200 mg/m2) were given on day 1

twice daily for two weeks

followed by oxaliplatin 130 mg/m2.The chemotherapy was repeated every 4 weeks.All patients received 2 cycles at least.Efficacy and toxicities were evaluated according to the RECIST 1.1 standard.Results:All the 48 patients were assessable for response.There were 5(10.4%) complete remission(CR)

23(47.9%) partial remission(PR)

12(25.0%) stable disease(SD)

and 8(16.7%) progression disease(PD).The overall response rate was 58.3%.The disease control rate(DCR) was 83.3%.Median time to progression(TTP) and median survival time(MST) were 8.9 and 12.3 months

respectively.The major toxicities were neurosensory abnormity

leukopenia

nausea

hematologic toxicity and vomiting.Conclusion:The combination of S1

oxaliplatin

irinotecan and leucovorin has good clinical activity with acceptable toxicity in patients with advanced gastric cancer.

关键词

胃癌替吉奥奥沙利铂伊立替康亚叶酸钙

Keywords

gastric cancerS1oxaliplatinirinotecanieucovorin

references

Views

168

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impacts of LncRNA MYLK-AS1 on proliferation，apoptosis，and invasion of gastric cancer cells by regulating the miR-141-3p/STMN1 axis

miR-149-5p targets AEBP1 to inhibit migration and invasion of gastric cancer cells

Role of N⁶-methyladenosine mediated by methyltransferase-like 3 in oxaliplatin resistance of colorectal cancer

Meta-analysis on the relationship between cyclooxygenase-2 gene polymorphism and gastric cancer in Asian population

Effect of GM130 on O-linked glycosylation and adhesion of human gastric cancer cell line MKN-45

Related Author

Liu Jie

Xie Xingming

Niu Hongxia

Yang Xianzhi

Chen Yan

Jiang Lei

Min Guangtao

Wang Jun

Related Institution

Department of Gastrointestinal Surgery，The Third Affiliated Hospital of Zunyi Medical University/ The First People’s Hospital of Zunyi

The Sixth Ward，Department of General Surgery， The First Hospital of Lanzhou University

The First Clinical Medical College of Lanzhou University

Department of Clinical Laboratory，The Second Hospital of Shandong University/Tumor Marker Detection Engineering Laboratory of Shandong Province

Department of Gastroenterology,the Third People’s Hospital of Chongqing

⁰